InvestorsObserver
×
News Home

Is Zai Lab Ltd - ADR (ZLAB) Stock at the Top of the Biotechnology Industry?

Wednesday, April 14, 2021 11:28 AM | InvestorsObserver Analysts

Mentioned in this article

Is Zai Lab Ltd - ADR (ZLAB) Stock at the Top of the Biotechnology Industry?

The 60 rating InvestorsObserver gives to Zai Lab Ltd - ADR (ZLAB) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 92 percent of stocks in the Biotechnology industry, ZLAB’s 60 overall rating means the stock scores better than 60 percent of all stocks.

Overall Score - 60
ZLAB has an Overall Score of 60. Find out what this means to you and get the rest of the rankings on ZLAB!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Zai Lab Ltd - ADR Stock Today?

Zai Lab Ltd - ADR (ZLAB) stock is up 2.84% while the S&P 500 has fallen -0.03% as of 11:25 AM on Wednesday, Apr 14. ZLAB has gained $4.58 from the previous closing price of $161.29 on volume of 278,979 shares. Over the past year the S&P 500 has gained 45.48% while ZLAB has gained 178.31%. ZLAB lost -$3.46 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Zai Lab Ltd - ADR (ZLAB) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App